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Summary Pain and fatigue have been identified as core symptoms of fibromyalgia syndrome
(FMS). Since both symptoms are also characteristic of hypocortisolemic disorders, reduced
cortisol levels have been thought to promote an exacerbation of these FMS core symptoms by an
enhanced reactivity of interleukin-6 (IL-6) levels. The aim of the current study was to
investigate the pathophysiologic relevance of reduced cortisol levels for manifestation of
FMS core symptoms. Twelve female FMS patients with 15 female controls were compared
regarding the function of hypothalamus—pituitary—adrenal (HPA) axis and behavioral, endo-
crine and IL-6 responses after measuring the pressure pain thresholds (PPTs) at tender points.
Function of HPA axis was assessed by determining the cortisol awakening response, daytime
profile of cortisol secretion, low dose overnight dexamethasone suppression test (DST) and
glucocorticoid sensitivity (GC) of inflammatory cytokine production. While endocrine and IL-6
responses were determined by collecting blood and saliva samples behavioral responses were
assessed by pain and fatigue recordings of participants before and after PPT measurement using
visual analogue scale (VAS). Whereas FMS patients were found not to differ from controls in
cortisol awakening response, daytime profile of cortisol secretion and cortisol suppression after
overnight DST, they did exhibit a reduced GC sensitivity of inflammatory cytokine production.
PPT measurement did induce three times higher cortisol and four times higher IL-6 levels in
FMS patients, but no change in their ACTH levels. The enhanced IL-6 reactivity after PPT
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measurement was accompanied by an increase in the severity of FMS patients’ pain and fatigue
ratings. The findings of the present study provide evidence for the pathophysiologic relevance
of a disturbed glucocorticoid receptor (GR) function, rather than reduced cortisol levels for
the maintenance of FMS core symptoms.
# 2011 Elsevier Ltd. All rights reserved.
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Fibromyalgia syndrome (FMS) is a chronic disorder character-
ized by core symptoms widespread musculoskeletal pain,
fatigue and sleep disturbances for a duration of at least
three months (Wolfe, 1989). FMS is approximately nine times
more common among women than men and the prevalence
increases with age, affecting nearly 7% of women over 60
years (Wolfe et al., 1995).
Onset of FMS has been found to be preceded by either
prior life trauma or high workload and workplace bullying
(Imbierowicz and Egle, 2003; Kivima¨ki et al., 2004). Both
types of chronic stressors have been reported to be accom-
panied by alterations of the hypothalamus—pituitary—adre-
nal (HPA) axis as this neuroendocrine system is mainly
involved in the mediation of the stress response (for review
Tanriverdi et al., 2007). Stress-induced glucocorticoid (GC)
secretion is currently believed to protect the organism from
harmful effects of overshooting defense mechanisms, for
example by suppressing the synthesis of pro-inflammatory
cytokines, such as interleukin-6 (IL-6) in immune cells (e.g.
Sapolsky et al., 2000). Two different patterns of an altered
neuroendocrine HPA axis function have been characterized,
termed hypocortisolism and hypercortisolemia. Prior life
trauma and cumulative adversity have been associated with
both patterns of dysfunctional HPA axis function as this
chronic stressor was found to increase the risk for developing
posttraumatic stress disorder (PTSD) following a later trauma
and major depressive disorder (MDD) in later life (Edwards
et al., 2003; Keane et al., 2006). A hypocortisolemic pattern
is mainly characterized by reduced cortisol levels, enhanced
feedback sensitivity and increased sensitivity of peripheral
blood mononuclear cells (PBMCs) to glucocorticoids and
hence enhanced glucocorticoid (GC) sensitivity (Yehuda
et al., 1991, 2004). Main neuroendocrine features of hyper-
cortisolemia are enhanced cortisol levels, a diminished feed-
back sensitivity and reduced sensitivity of PBMCs to
glucocorticoids (Gillespie and Nemeroff, 2005). While pain
and fatigue have been identified as core symptoms of hypo-
cortisolemic disorders hypercortisolemia has been reported
to be manifested mainly in fatigue and cognitive dysfunction
(Geiss et al., 2005; Fries et al., 2005; Miller et al., 2009). Both
neuroendocrine patterns have been found to be accompanied
by elevated cytokine levels. While a reduced cortisol avail-
ability is thought to account for elevated cytokine levels in
hypocortisolism an attenuated sensitivity of PBMCs to gluco-
corticoids has been related to increased cytokine levels in
hypercortisolemia (Geiss et al., 2005; Fries et al., 2005;
Miller et al., 2009; Rohleder et al., 2010).
There is evidence for both a hypercortisolemic and hypo-
cortisolemic state in FMS. In more detail, FMS patients have
been reported to exhibit an elevated cortisol profile (Catley
et al., 2000), but also to display an attenuated cortisol
response during the first hour after awakening (Weissbeckeret al., 2006; Klingmann et al., 2008). Furthermore, FMS
patients have been identified to exhibit a lower glucocorti-
coid receptor (GR) binding of their PBMCs to glucocorticoids
and hence reduced GC sensitivity (Lentjes et al., 1997). In
contrast, neither Wingenfeld et al. (2008) nor Macedo et al.
(2008) did find any difference between FMS patients and
controls in their GC sensitivity of circulating monocytes.
Inconsistent findings have been reported also for the status
of the feedback sensitivity in FMS patients as enhanced
feedback sensitivity has been detected by one study (Win-
genfeld et al., 2007), but several other studies did show a
reduced feedback sensitivity (Ferraccioli et al., 1990; Griep
et al., 1998).
Likewise, increased IL-6 levels have been detected pre-
viously in supernatants of stimulated FMS patients’ PBMCs by
Wallace et al. (2001), but recent studies did not find any
difference between FMS patients and controls in their IL-6
levels after controlling for depressive symptoms (Gu¨r et al.,
2002; Bazzichi et al., 2006; Wang et al., 2008).
Since pain and fatigue have been identified as core symp-
toms of FMS we assumed that FMS patients’ hypocortisolemic
pattern might promote an exacerbation of pain and fatigue
through increased inflammatory signaling. The aim of the
present study was to test whether low cortisol responses to
the measurement of pressure pain thresholds (PPTs) at tender
points were associated with enhanced reactivity of IL-6 levels
in FMS patients as compared with controls.
2. Methods
2.1. Participants
Twelve female patients with FMS were recruited from a local
support group in Trier, Germany. All patients were diagnosed
with FMS by their rheumatologists according to the 1990
American College of Rheumatology classification criteria
(Wolfe et al., 1990). All patients fulfilled the inclusion cri-
teria of (1) being <60 years old; (2) having a body mass index
(BMI) <35 kg/m2; (3) not having a history of major physical
(including rheumatic conditions), or psychiatric illness; (4)
had not received epidural corticosteroid injections and anti-
depressant medication at the clinical and low dose during one
year preceding the study; and (5) were able to discontinue
either anti-inflammatory medication and/or hormone repla-
cement therapy for at least 4 weeks prior to the study. As a
control group, fifteen female, pain-free participants
matched for age and education were recruited from adver-
tisements placed on bulletin boards and in local newspapers.
Donors having elevated Westergen erythrocyte sedimenta-
tion rates (WESR) and increased total neutrophil counts, for
instance, two weeks preceding the study were excluded from
participation. The study was approved by the Ethics Com-
mittee of the University of Trier and all participants gave
their informed consent to participation.
Table 1 Overview of the experimental examinations the subjects undergoing each day.
Day 1 Day 2 Day 3 Day 4
Procedure Collection of saliva
samples to determine
the cortisol awakening
response (CAR)
immediately after
awakening at 0700 h
Collection of saliva and
blood samples before
and after measurement
of pressure pain thresholds
(PPTs) at tender points,
starting at 1630 h and
ending at 2400 h
Collection of two blood
samples to determine
the glucocorticoid (GC)
sensitivity of inflammatory
cytokine production and
white blood cell (WBC)
count at 11 00 h
Collection of saliva
samples to determine
cortisol awakening
response (CAR)
immediately after
awakening at 0700 h
and daytime profile
of cortisol secretion
starting at 1000 h
and ending at 2200 h
Collection of saliva
samples to determine
daytime profile,
beginning at 1000 h
and ending at 2200 h.
Ingestion of 0.5 mg
dexamethasone at 2200 h
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As depicted in Table 1, the experimental examinations were
conducted on four consecutive days. On the first day, cortisol
awakening response (CAR) and daytime profile of cortisol
secretion were assessed by instructing participants to collect
one saliva sample immediately after awakening at 0700 h, as
well as four saliva samples in intervals of 15 min after
awakening. Further seven saliva samples were obtained by
the participants at intervals of 2 h, beginning at 1000 h.
Participants were asked to refrain from eating for at least
30 min before saliva collection. On the second day, the
experimental session was started by inserting a catheter into
the antecubital vein (Braun, Melsungen, Germany) within 1 h
after arrival of participants in the laboratory of the Center
for Psychobiological and Psychosomatic Research, University
of Trier (Germany) at 1300 h. In order to avoid a stimulatory
effect of physical activity or psychological stress on IL-6 and
cortisol levels participants were instructed to take a rest
between 1400 h and 1630 h (Ostrowski et al., 1998; Von Ka¨nel
et al., 2006).
Baseline measurement of differential white blood cell
(WBC) count, free cortisol, ACTH, catecholamine and IL-6
levels were performed by taking blood and saliva samples 30,
20, 10 and 1 min before PPT measurement. Participants
underwent the algesimetric procedure for a duration of
45 min, starting at 1700 h. Post-algesimetric measurements
of free cortisol, ACTH, catecholamines and IL-6 levels were
obtained by collecting saliva and blood samples 1, 10, 20, 30,
90, 150, 195, 240, 285, 330 and 375 min after PPT measure-
ment, ending at 2400 h.
Additionally, at all pre- and postalgesimetric time points,
participants rated their pain and fatigue intensities by using a
100 mm visual analogue scale (VAS) for pain (VAS-P) and
fatigue (VAS-F), respectively. The subjects also measured
their core body temperature (CBT) at four time points,
beginning at 3 p.m. and thereafter in time intervals of 3 h.
Four hours after conclusion of PPT measurement, all parti-
cipants received a standard meal. On day 3, two blood
samples were collected at 1100 h to determine the gluco-
corticoid (GC) sensitivity of inflammatory cytokine produc-
tion by circulating monocytes. In the night of day 3 at 2200 h,participants ingested 0.5 mg dexamethasone (DEX; Jena-
pharm, Jena, Germany) and collected on the day thereafter
five saliva samples during the first hour after awakening at
0700 h and additional seven saliva samples in intervals of 2 h
(Yehuda et al., 1993).
2.3. Psychological measurements
For assessment of the severity of fatigue symptoms a vali-
dated German version of the Multidimensional Fatigue Inven-
tory (MFI) (Gaab et al., 2002a) has been employed. As in the
English version, the MFI consists of five scales, each with four
items, which address different manifestations of fatigue,
including General, Physical and Mental Fatigue. The partici-
pants were asked to assess on a seven-point rating scale how
frequently they experienced specific fatigue symptoms dur-
ing previous days.
For assessment of chronic stress levels the validated Ger-
man version of the Trier Inventory for the Assessment of
Chronic Stress (TICS) (Schulz and Schlotz, 1999) has been
used. The 39-item TICS consists of six scales which address
different origins of subjective stress levels, including work
overload, worries, social stress, lack of recognition, work
discontent, and intrusive memories. The participants were
asked to judge on a five-point rating scale how frequently
they experienced specific stress situations during the year
preceding the onset of their disease.
Presence of major depressive disorder (MDD) was
screened by using the German version of the Center for
Epidemiological Studies Depression Scale (CES-D) and the
German version of the Patient Health Questionnaire (PHQ-
D) in their validated forms (Hautzinger and Bailer, 1993; Lo¨we
et al., 2002). The CES-D assesses the frequency of depressive
symptoms during the previous week. Since somatic symptoms
comprising depression are thought to be confounded with
symptoms of chronic pain patients a cut off score of 19 has
been recommended to identify MDD in chronic pain patients
(Magni et al., 1994; Turk and Okifuji, 1994). The PHQ-D
assesses the frequency of nine depressive symptoms during
the previous two weeks and 13 physical symptoms during the
previous month according to criteria of Diagnostic and Statis-
tical Manual of Mental Disorders (DSM) (Spitzer et al., 1999).
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MDD and subthreshold diagnosis for somatoform disorder
(Kroenke et al., 2001, 2002).
Subjective pain experience was assessed with the vali-
dated German version of the McGill Pain Questionnaire (SES)
(Geissner, 1995). This questionnaire allows the separate
assessment of the sensory (MPQ-S) and affective (MPQ-A)
qualities of pain, as well as providing a total pain score.
Written instructions were slightly modified to ask patients
specifically to describe their musculoskeletal pain.
2.4. Measurement of pressure pain thresholds
(PPTs) at tender points
Pressure pain thresholds (PPTs) were determined bilaterally
at four different tender points including suboccipital muscle
insertions (occiput), the midpoint of the upper border (tra-
pezius) origins, above the scapuala spine near the medial
border (supraspinous) and in upper outer quadrants of but-
tocks in anterior fold of muscle (gluteal) by using a pressure
algometer (Somedia Sales AB, Munich, Germany). Ascending
series of pressure in a rate of 20 kilopascal (kPa)/s were
applied to each muscle until the pressure was first perceived
as painful. PPTs were determined twice at each tender point
on the right and left side of the body in a randomized order.
Application of each pressure series was separated by at least
20 s. The participants underwent the measurement of PPTs in
a prone position. For each tender point PPTs were aggregated
for the right and left side.
Participants were familiarized with the pressure algome-
try prior to examination by bilaterally measuring PPTs on the
joint capsules of both hands and ankles. This pre-trial assess-
ment was conducted with participants being in a sitting
position.
2.5. Biochemical measures
Separate EDTA blood samples were drawn for determination
of IL-6, norepinephrine (NE), epinephrine (EPI) and ACTH
levels (Sarstedt, Nu¨mbrecht, Germany). In order to prevent
IL-6 from being metabolized, blood was drawn into pre-
chilled tubes and centrifuged at 1000  g for 10 min. Blood
samples for determination of catecholamines and ACTH were
centrifuged at 3000 rpm for 10 min. Plasma from all samples
was aliquoted and stored at 80 8C until later analysis.
Catecholamine levels were determined by high-perfor-
mance liquid chromatography with electrochemical detec-
tion (Chromsystems, Germany; Smedes et al., 1982), and a
commercial chemiluminescence assay (Nichols Institute, San
Juan Capistrano, USA) was used to detect ACTH levels.
Plasma IL-6 levels were determined by a high sensitivity
quantitative sandwich enzyme immunoassay (ELISA, R&D
Systems, Minneapolis, MN, USA). The lowest limit of detec-
tion was 0.156 pg/ml. The intra- and interassay coefficient of
variation (CVs) of a concentration at 1.99 pg/ml was 0.15%
and 5%, respectively. Saliva samples for cortisol measure-
ment were collected using saliva collection device (Salivette,
Sarstedt, Nu¨rnbrecht, Germany) and stored at 20 8C until
analysis. Free cortisol in saliva was measured by a time
resolved fluorescence immunoassay as described in detail
previously (Dressendo¨rfer et al., 1992).Glucocorticoid sensitivity of inflammatory cytokine pro-
duction by circulating monocytes was measured as described
earlier (DeRijk et al., 1996). In brief, 5 ml whole blood was
diluted 10:1 with 0.9% saline, 400 ml of diluted whole blood
was coincubated with 50 ml of lipopolysaccharide (LPS) (E.
coli, DifcoSigma, Augsburg, Germany) and 50 ml of dexa-
methasone (DEX) in different concentrations (Sigma, Deisen-
hofen, Munich, Germany) on a 24-well-plate (Greiner,
Nuertingen, Germany) for 6 h at 37 8C in a humidified incu-
bator containing 5% CO2. The final concentrations were
30 ng/ml LPS, and 0, 1010, 109, 108, 5  108, 107
and 106 M DEX. After centrifugation for 10 min at 4 8C
and 2000  g the supernatants were aliquoted and stored
at 80 8C until analysis. Supernatant concentrations of tumor
necrosis factor-a (TNF-a) and IL-6 were determined by
employing a commercial ELISA (BD Pharmingen, San Diego,
CA, USA). The detection limits of the ELISAs were 9.4 and
15.5 pg/ml for IL-6 and TNF-a, respectively. The intra- and
interassay CVs were below 10%.
2.6. Statistical analysis
Cortisol awakening responses (CAR) were assessed by com-
puting two indices: The total cortisol secretion within 1 hr
postawakening was quantified using the area under the curve
(AUC) with respect to ground (AUCG1), and the increase of
cortisol after awakening was quantified using the AUC with
respect to the baseline (AUCI) (Pruessner et al., 2003). Day-
time cortisol secretion was estimated by computing the AUC
with respect to ground for cortisol levels between 1000 h and
2200 h (AUCG2; Wu¨st et al., 2000). Reactivity of IL-6 levels
and changes in pain and fatigue ratings after PPT measure-
ment were quantified by computing the AUC with respect to
ground between baseline and 375 min post-testing (Pruessner
et al., 2003).
Based on previous findings, feedback sensitivity of the HPA
axis was assessed by quantifying the extent and duration of
cortisol suppression after overnight dexamethasone suppres-
sion test (DST) (Yehuda et al., 1991, 1993).
An enhanced HPA axis feedback sensitivity is character-
ized by post-dexamethasone (post-DEX) free cortisol levels
which are significantly reduced in comparison with controls
and below 2 nmol/L during the first hour after awakening and
time interval ranging from 1000 h to 2200 h (Gaab et al.,
2002b; Geiss et al., 2005). A reduced feedback sensitivity has
been characterized by post-DEX levels which are significantly
elevated in comparison with controls and above 5 nmol/L
during the first hour after awakening and time interval
ranging from 1000 h to 2200 h (Lieb et al., 2004). To quantify
the extent and duration of cortisol suppression areas under
post-DEX cortisol values with respect to ground were calcu-
lated for the first hour after awakening (AUCD1), and between
1000 h and 2200 h (AUCD2).
Glucocorticoid sensitivity (GC) of circulating monocytes
was assessed by determining the dosage of DEX required to
induce a 50% inhibition of LPS-induced TNF-a and IL-6 pro-
duction (IC50; Geiss et al., 2005).
The time course of free cortisol, ACTH, catecholamines
and IL-6 levels was analyzed by performing two-way analyses
of variance (ANOVA) for repeated measurements with the
between subjects variable ‘‘group’’ and the within-subjects
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induced TNF-a and IL-6 production, two-way analyses of
variance (ANOVA) for repeated measurements with the
variables ‘‘group’’ and ‘‘dose’’ were computed. Degrees
of freedom were adjusted where appropriate employing
the Greenhouse-Geisser approach to correct for violation of
the sphericity assumption (Hays, 1981). Subsequent uni-
variate analyses (ANOVAs) were employed to ascertain
which subgroup, dose or time point accounts for the
revealed significant main effect. Comparisons between
groups in demographic characteristics and psychometric
variables were conducted by performing multiple Student’s
t-tests. A Bonferroni correction of the error probability
was performed taking into account the multiple compar-
isons (Hays, 1981). Since the aim of the present study was
to test whether measurement of PPTs at tender points is a
suitable method to induce enhanced IL-6 levels in FMS
patients and not to analyze the change process of IL-6
levels after PPT measurement we did not take advantage
of more potent analytical approaches such as multilevel
modeling. Statistical significance was determined at an
alpha level of 0.05. For relating psychological parameters
to IC50 and total-time integrated in vivo IL-6 response to
PPT measurement, Pearson correlation coefficients and
partial correlation coefficients were computed. Effect sizesTable 2 Demographic and psychometric characteristics of patien
Demographic characteristics
Age (years) 
Time since diagnosis of fibromyalgia (in months) 
Body mass index (means  SE) 
Anti-inflammatory medication and/or hormone replacement the
No medication (%, n) 
Menopause (%, n) 
Psychometric characteristics
Trier Inventory for the Assessment of Chronic Stress (TICS)
Work overload 
Worries 
Social stress 
Lack of recognition 
Work discontent 
Intrusive memories 
German version of the McGill Pain Questionnaire (SES)
Sensory qualities of pain 
Affective qualities of pain 
German version of Multidimensional Fatigue Inventory (MFI)
General fatigue 
Physical fatigue 
Mental fatigue 
Reduced activation 
Reduced motivation 
German version of Center for Epidemiologic Studies Depression 
German version of Patient Health Questionnaire (PHQ)
Threshold diagnosis of major depressive disorder (%, n) 
Subthreshold diagnosis of somatoform disorder (%, n) 
Data are represented as mean  SEM.
* Indicates significant differences between FMS patients and controls
** Indicates significant differences between FMS patients and controls(ES) were additionally computed. While product moment
(r) was computed for between-subject comparisons partial
eta squared (h2) was calculated for within-subject compar-
isons (Cohen, 1987).
3. Results
3.1. Demographic and psychometric variables
As reported in Table 2, FMS patients did not differ from controls
on most demographic characteristics, with the exception that
the majority of FMS patients did take anti-inflammatory med-
ication including Devil’s claw extract and nonsteroidal anti-
inflammatory drugs such as diclofenac until four weeks before
examinations. FMS patients scored higher on the TICS sub-
scales ‘‘lack of recognition’’ [F(1,24) = 6.512, p < 0.018] and
‘‘work discontent’’ [F(1,24) = 4.826, p < 0.038]. Further-
more, FMS patients did score significantly higher on all MFI
subscales (all Ps < 0.05), and the German version of McGill
Pain Questionnaire (SES) indicating that they experienced the
sensory [F(1,23) = 14.125, p < 0.001] and affective [F(1,
23) = 92.576, p < 0.000] qualities of pain more intensely.
FMS patients reported a significantly higher frequency of
depressive symptoms than controls [F(1, 22) = 5.938,ts with fibromyalgia syndrome (FMS) and controls.
Patients with FMS Controls
50  2.07 41  2.98
143.70  33.925
26.30  0.363 26.47  1.01
rapy (%, n) 75 (9) 7 (1)
25 (3) 93 (14)
25 (3) 13 (2)
24.250  1.919 18.785  2.425
16.7500  1.349 14.857  0.740
15.0000  0.8528 15.500  0.521
20.500  1.0624 ** 17.071  0.848
14.250  0.970 * 11.928  0.518
16.000  1.193 14.571  0.992
26.90  3.128 ** 16.60  0.86
42.20  3.268 ** 15.47  0.70
14.800  1.331 ** 6.500  0.817
13.800  1.459 ** 7.357  0.9978
13.600  1.641 ** 5.714  0.8012
13.500  1.4624 ** 5.642  0.874
12.100  1.754 ** 7.142  0.776
Scale (CES) 24.10  3.99 * 14.57  1.695
17 (2)
17 (2)
 ( p < 0.05).
 ( p < 0.01).
Figure 1 Comparison of the groups regarding free cortisol
levels (A) during the first hour after awakening and (B) interval
ranging from 1000 h to 2200 h. Data are expressed as
means  S.E.M.
676 A. Geiss et al.p < 0.023] and two FMS patients did conform with criteria for a
threshold diagnosis of a moderately severe MDD.
3.2. Baseline measurements
3.2.1. Pressure pain thresholds (PPTs) at tender points
FMS patients had significantly lower PPTs at all examined
tender points, including suboccipital muscle insertions (occi-
put) [FMS patients: 219.56 kPa  47.08; Controls:
433.19 kPa  15.63], the midpoint of the upper border (tra-
pezius) origins [FMS patients: 249.25 kPa  55.26; Controls:
431.72 kPa  7.11], above the scapuala spine near the med-
ial border (supraspinous) [FMS patients: 255.75 kPa  49.38;
Controls: 446.28 kPa  10.32] and in upper outer quadrants
of buttocks in anterior fold of muscle (gluteal) [FMS patients:
258.87 kPa  46.96; Controls: 437.35 kPa  11.33] (all
Ps < 0.001).
3.2.2. Differential white blood cell (WBC) count
FMS patients did differ from controls on subsets of white blood
cells, showing significantly higher leukocyte [FMS patients:
7.18  106 cells/ml  0.75; Controls: 5.54  106 cells/ml 
0.37; F(1, 21) = 4.79, p < 0.04], neutrophil [FMS patients:
4.29  106 cells/ml  0.65; Controls: 2.81  106 cells/ml 
0.36; F(1, 21) = 4.67, p < 0.04] and monocyte counts [FMS
patients: 0.55  106 cells/ml  0.07; Controls: 0.37  106
cells/ml  0.01; F(1, 21) = 10.47, p < 0.004].
3.3. Assessment of HPA axis function
3.3.1. Cortisol levels in response to awakening and
during the day
Fig. 1 displays free cortisol levels during the first hour after
awakening and the interval ranging from 1000 h to 2200 h.
ANOVA for repeated measures revealed a significant main
effect of time [F(2.04, 51.13) = 9.66, p < 0.001, h2 = 0.28],
but no significant group by time interaction [F(2.05,
51.14) = 0.85, p < 0.44, h2 = 0.03], thereby indicating that
FMS patients and controls did exhibit a similar cortisol
response during the first hour after awakening.
In further support of this notion FMS patients did not differ
significantly from controls in their cortisol secretion during the
first hour after awakening (AUCG1), and adrenocortical
response to awakening (AUCI) [F(1, 25) = 2.72, p < 0.11,
r = 0.07; F (1, 25) = 1.331, p < 0.26, r = 0.04, respectively].
Comparison between FMS patients and controls regarding
their cortisol levels during the day revealed neither a signifi-
cant group by time interaction [F(4.14, 91.05) = 1.53,
p < 0.20, h2 = 0.07] nor main effect of group [F(1,
22) = 0.06, p < 0.81, h2 = 0.003] indicating similarity of FMS
patients and controls in their cortisol levels throughout the day.
Furthermore, there was no significant difference between FMS
patients and controls in their AUC of cortisol levels between
1000 h and 2200 h (AUCG2) [F(1, 22) = 0.12, p < 0.72].
3.3.2. Feedback sensitivity of the pituitary—adrenal
axis
Fig. 2 displays the post-DEX cortisol values during the first
hour after awakening and the interval ranging from 1000 h to
2200 h. Statistical analysis of the post-DEX cortisol values
during the first hour after awakening revealed a significantgroup by time interaction [F(1.76, 44.00) = 3.60, p < .04,
h2 = 0.13]. Post hoc analysis ascertained FMS patients as
displaying significantly higher post DEX cortisol values
45 min [F(1,25) = 6.59, p < 0.01] and 60 min [F(1,
25) = 3.94, p < 0.05] postawakening. There was a statistical
trend for a higher post-DEX cortisol secretion within 1 hr
postawakening (AUCD1) in FMS patients as compared with
controls [F(1, 25) = 3.21, p < 0.09, r = 0.10].
Again, comparing post-DEX cortisol values between 1000 h
and 2200 h revealed a significant group by time interaction
[F(1.45, 33.42) = 4.63, p < 0.03, h2 = 0.17]. Post hoc univari-
ate ANOVAs confirmed that FMS patients had similar post-DEX
values as controls between 1000 h and 2000 h, but signifi-
cantly higher post-DEX values at 2200 h [F(1,24) = 7.41,
p < 0.01]. FMS patients did display similar AUCD2 [F(1,
23) = 0.001, p < 0.98, r = 0.00] as controls.
3.3.3. Glucocorticoid (GC) sensitivity of inflammatory
cytokine production by circulating monocytes
As depicted in Fig. 3A, significantly higher concentration of
DEX was necessary to induce a 50% inhibition of FMS patients’
LPS-induced IL-6 production in comparison with controls
Figure 3 Differences between FMS patients and controls in
dosages of dexamethasone being required to induce a 50%
inhibition of the LPS-induced (A) IL-6 production and (B)
TNFa-production in peripheral blood monocytes (IC50). The
IC50 is inversely related to the sensitivity of monocytes to the
immunosuppressive effects of cortisol. A higher IC50 indicates a
lower sensitivity of monocytes to the immunosuppressive effects
of cortisol. * Indicates significant difference between FMS
patients and controls ( p < 0.05). Data are expressed as
means  SEM.
Figure 2 Cortisol suppression after ingestion of 0.5 mg dexa-
methasone (A) during the first hour after awakening and (B)
interval ranging from 1000 h to 2200 h. * Indicates significant
differences between FMS patients and healthy controls
( p < 0.05). ** Indicates significant differences between FMS
patients and healthy controls ( p < 0.01). Data are expressed
as means  S.E.M.
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required for a 50% inhibition of the LPS-induced TNFa pro-
duction the difference between FMS patients and controls in
their IC50 failed to reach significance [F(1,20) = 2.13,
p < 0.16, r = 0.09].
3.3.4. Bivariate associations of psychological variables
with glucocorticoid sensitivity
In all participants, dosage of DEX which is required to induce
a 50% inhibition of LPS-induced TNF-a and IL-6 production
was significantly correlated with subscales of the MFI, includ-
ing ‘‘General Fatigue [r = 0.475, p < 0.01 and r = 0.533,
p < 0.008, respectively], ‘‘Mental Fatigue’’ [r = 0.375,
p < 0.05 and r = 0.531, p < 0.008, respectively], ‘‘Reduced
motivation’’ [r = 0.407, p < 0.03 and r = 0.57, p < 0.004,
respectively] and ‘‘Reduced Activation’’ [r = 0.405,
p < 0.03 and r = 0.375, p < 0.05, respectively]. Whereas
MFI subscale ‘‘Physical Fatigue’’ was significantly correlated
with IC50 for LPS-induced TNFa production [r = 0.361,p < 0.05] the correlation with the DEX dose being required
to induce a 50% inhibition of the LPS-induced IL-6 production
failed to reach significance [r = 0.283, p < 0.11]. With the
exception of the correlation between MFI subscale ‘‘General
Fatigue’’ and required DEX dose to induce a 50% inhibition of
LPS-induced IL-6 production the correlations between MFI
subscales and required DEX dose to induce a 50% inhibition of
LPS-induced TNFa and IL-6 production did disappear after
controlling for the effect of total-time integrated in vivo IL-6
response to PPT measurement [all Ps > 0.07].
3.4. Behavioral, endocrine and interleukin-6
responses to pressure pain threshold (PPT)
measurement
3.4.1. Fatigue and pain response to PPT measurement
The time courses of fatigue and pain ratings before and after
PPT measurement are depicted in Fig. 4. Since FMS patients
Figure 4 Changes in the severity of (A) fatigue and (B) pain
ratings after conclusion of pressure pain threshold (PPT) mea-
surement. Subjects scored their fatigue and pain intensity on a
visual analogue scale for fatigue (VAS-F) and visual analogue
scale for pain (VAS-P), respectively. ** Indicates significant dif-
ferences between FMS patients and healthy controls ( p < 0.01).
Data are expressed as means  S.E.M.
Figure 5 Changes in plasma (A) epinephrine (EPI) and (B)
norepinephrine (NE) levels after conclusion of pressure pain
threshold (PPT) measurement. * Indicates significant differences
between FMS patients and healthy controls ( p < 0.05). ** Indi-
cates significant differences between FMS patients and healthy
controls ( p < 0.01). Data are expressed as means  S.E.M.
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23) = 779.64, p < 0.0001] and 20 min [F(1, 23) = 781.23,
p < 0.0001] before PPT measurement the averaged fatigue
scores were considered as a covariate in the subsequent
analysis. ANOVA for repeated measures revealed a significant
interaction between group and time [F(3, 69.07) = 89.96,
p < 0.0001, h2 = 0.80] (Fig. 4A). Post hoc analysis showed
that pressure application on tender points did aggravate
sleepiness in FMS patients as their VAS-F scores increased
significantly 60 min [F(1,23) = 1726,74, p < 0.0001] and
90 min post-testing [F(1,23) = 22417.72, p < 0.001].
For changes in pain ratings after PPT measurement, there
was a statistical trend for group by time interaction [F(2.19,
43.8) = 2.7, p < 0.08, h2 = 0.12] after controlling for FMS
patients’significantly higher pain scores under pre-algesimetricconditions [F(1, 23) = 39.01, p < 0.001]. Univariate analyses
revealed that VAS-P scores of FMS patients did increase by
10 units on average within 10 min after pain measurement
[F(1, 20) = 43.05, p < 0.0001], thereby revealing that PPT
measurement exacerbated sleepiness and pain intensity in
FMS patients.
3.4.2. Catecholamine response to PPT measurement
Fig. 5 shows epinephrine (EPI) and norepinephrine (NE) levels
before and after PPT measurement. For epinephrine levels,
ANOVA for repeated measures indicated a statistical trend for
group by time interaction [F(2,44) = 2.89, p < 0.07,
h2 = 0.12]. Univariate analyses confirmed a statistical trend
for higher epinephrine levels 30 min pre-testing [F(1,
22) = 3.69, p < 0.07] in controls and identified significant
lower epinephrine levels 60 min post-testing in this subgroup
[F(2,44) = 5.55, p < 0.007] (Fig. 5A). For norepinephrine
levels, ANOVA for repeated measures showed a significant
main effect of group [F(1,22) = 11.3, p < 0.003, h2 = 0.34],
but group by time interaction failed to reach significance
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lyses revealed that the significant main effect is due to FMS
patients’ significantly elevated norepinephrine levels 10 min
before [F(1,22) = 6.04, p < 0.02] and 10 min after PPT mea-
surement [F(1,22) = 13.08, p < 0.002], thereby pointing to
their higher sympathoadrenal activity.
3.4.3. ACTH response to PPT measurement
Compared with controls, FMS patients exhibited significantly
lower ACTH levels 30 and 10 min before PPT measurement
(F(1,21) = 7.24, p < 0.02; F(1, 21) = 5.69, p < 0.03, respec-
tively) (Fig. 6A). In order to control for this group difference,
the average of the baseline ACTH levels was added to theFigure 6 Changes in plasma (A) ACTH levels, (B) free cortisol leve
(PPT) measurement. * Indicates significant differences between FMS
differences between FMS patients and healthy controls ( p < 0.01). repeated measures ANOVA as a covariate. A significant inter-
action between group and time emerged for ACTH levels
(F(1.78, 37.37) = 7.4, p < 0.003, h2 = 0.26) after controlling
for baseline ACTH levels. While controls’ ACTH levels
declined from pre- to 10 min post-testing [F(1,21) = 3.71,
p < 0.07], FMS patients’ ACTH levels did not change during
the observation period.
3.4.4. Cortisol response to PPT measurement
Similar to ACTH, FMS patients exhibited significantly lower
cortisol levels 30 min (F(1,23) = 4.50, p < 0.04) before PPT
measurement (Fig. 6B). ANOVA for repeated measures
revealed a significant group by time interaction afterls and (C) IL-6 levels after conclusion of pressure pain threshold
 patients and healthy controls ( p < 0.05). ** Indicates significant
Data are expressed as means  S.E.M.
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[F(2.09, 46.02) = 4.9, p < 0.011, h2 = 0.18]. Post hoc analyses
revealed that FMS patients had significantly higher cortisol
levels after PPT measurement for 10 min [F(1,23) = 11.04,
p < 0.003], 90 min [F(1,23) = 7.01, p < 0.01] and 375 min
[F(1,23) = 27.22, p < 0.0001]. From baseline levels, cortisol
increased approximately 300% at 10-min post-testing, then
returned below baseline levels and increased again at 240-
min post-testing, thereby indicating that PPT measurement
induced considerable adrenocortical activation in FMS patients.
3.4.5. Interleukin-6 response to PPT measurement
Statistical comparison of pre-algesimetric with post-algesi-
metric IL-6 levels revealed a significant group by time inter-
action [F(3.23, 61.35) = 4.77, p < 0.004, h2 = 0.20] (Fig. 6C).
While FMS patients did not differ from controls in IL-6 levels
before PPT measurement [F(1, 21) = 2.71, p < 0.11] they
exhibited significantly enhanced IL-6 levels during the whole
post-testing session including 30 min [F(1,21) = 10.5,
p < 0.004], 90 min [F(1,20) = 22.22, p < 0.0001], 150 min
[F(1, 21) = 22.53, p < 0.0001], 195 min [F(1,21) = 28.57,
p < 0.0001], 240 min [F(1,21) = 15.62, p < 0.001], 285 min
[F(1,21) = 18.51, p < 0.001], 330 min [F(1, 21) = 15.03,
p < 0.001] and 375 min [F(1,20) = 7.81, p < 0.011] post-test-
ing. In terms of FMS patients’ IL-6 increase, their IL-6 levels
peaked at approximately 300% above baseline at 240-min
post-testing and did not return to baseline levels at the end of
post-testing session, thereby revealing their enhanced IL-6
reactivity in response to PPT measurement. In further sup-
port of FMS patients’ enhanced IL-6 reactivity after PPT
measurement they exhibited a significantly higher total-time
integrated IL-6 response as compared with controls [F(1,
19) = 16.26, p < 0.001, r = 0.42]. IL-6 AUC was significantly
associated with fatigue (r = 0.77, p < 0.0001) and pain rat-
ings (r = 0.60, p < 0.001) AUC. There was a statistical trend
for a positive correlation between in vitro GC sensitivity of
LPS-induced IL-6, but not TNFa production with total-time
integrated in vivo IL-6 response to PPT measurement
[(r = 0.34, p < 0.09) and (r = 0.21, p < 0.21), respectively].
4. Discussion
This study was conducted to examine whether FMS patients’
reduced cortisol levels are associated with an exacerbation of
pain and fatigue ratings, which may be mediated by an
increased IL-6 reactivity after PPT measurement. This is to
the best of our knowledge the first study to test for endocrine
and immune characteristics in FMS patients that are in agree-
ment with the hypothesized pathophysiological relevance of a
hypocortisolemic pattern for manifestation of FMS core symp-
toms. In summary, FMS patients’ awakening response, daytime
profile of cortisol secretion and cortisol suppression after
ingestion of a low dose DEX were found to be normal. In
contrast, IL-6 production in circulating monocytes of FMS
patients was found to be less sensitive to the immunosuppres-
sive actions of glucocorticoids. While PPT measurement did not
change ACTH levels in FMS patients, we found elevated nor-
epinephrine levels, together with three times higher cortisol
levels and four times higher IL-6 levels in FMS patients com-
pared with controls. The enhanced IL-6 reactivity was accom-
panied by a reduced sensitivity of circulating monocytes toglucocorticoid inhibition of IL-6 production and by an aggrava-
tion of pain and fatigue ratings after PPT measurement.
Overall, the findings of the present study are in agreement
with the hypothesis of a pathophysiological relevance of a
disturbed GR signaling pathway, rather than reduced cortisol
levels for the maintenance of FMS core symptoms fatigue and
pain. The reduced sensitivity of circulating monocytes to the
immunosuppressive effects of glucocorticoids may permit
the maintenance of FMS core symptoms fatigue and pain
by an insufficient inhibition of cytokine production.
The revealed similarity between FMS patients and controls
in their cortisol awakening response does conflict with pre-
vious findings as FMS patients were found to exhibit an atte-
nuated cortisol awakening response (Weissbecker et al., 2006;
Klingmann et al., 2008). Lack of control for confounding
variables of cortisol awakening response such as trauma his-
tory or gestational length may account for the inconsistency.
During the first hour after awakening FMS patients’ post-DEX
cortisol values were found to be below the cut-off value of
2 nmol/L, but significantly elevated in comparison with con-
trols. During the remainder of the post-DEX study day, FMS
patients did exhibit similar post-DEX cortisol values as controls.
On average, FMS patients’ post-DEX cortisol values were below
5 nmol/L during the time interval ranging from 1000 h to
2200 h. Since FMS patients’ post-DEX cortisol values did not
fulfill all criteria of either an enhanced or a reduced HPA axis
feedback sensitivity the present findings do point to a normal
HPA axis feedback sensitivity in this population. Differences
between current and previous studies in DEX dosage, amount of
post-DEX cortisol measurements and measured cortisol frac-
tion may account for the inconsistent findings. While Ferrac-
cioli et al. (1990) did use 1 mg DEX for assessing feedback
sensitivity subjects in the present study did ingest 0.5 mg DEX.
Both dosages have been reported to differ in their sensitivity to
discriminate normal from altered feedback sensitivity as a
dosage of 1 mg DEX causes a total and a dosage of 0.5 mg
DEX induces a partial suppression of the adrenal cortisol secre-
tion (Yehuda, 1997). Limitation to one post-DEX total cortisol
measurement at 0800 h in Wingenfeld’s study may influence
DSTresults as post-DEX cortisol values have been shown to vary
markedly 9 and 16 h following DEX ingestion (Lowy and Meltzer,
1987). DST results may be also influenced by limitation of the
measured cortisol fraction to total cortisol levels because total
cortisol levels are modulated by corticosteroid-binding globu-
lin (CBG) levels (Rosner, 1990). Since FMS patients have been
shown to exhibit reduced CBG levels, exaggerated cortisol
suppression in Wingenfeld’s study may reflect, in part, FMS
patient’s lower CBG levels (Lentjes et al., 1997).
In the current study a significantly higher DEX dose was
found to be required to induce a 50% inhibition of the LPS-
induced IL-6 production in FMS patients. This finding is
indicative of a reduced GC sensitivity of circulating mono-
cytes in these patients. The reduced sensitivity of circulating
monocytes to the immunosuppressive effects of glucocorti-
coids is accompanied by a higher frequency of experienced
fatigue symptoms, thereby suggesting the pathophysiologic
relevance of reduced GC sensitivity of circulating monocytes
for FMS core symptoms.
A reduced GC sensitivity of circulating monocytes has
been related to a disturbance within the transduction process
of the cortisol signal into cytokine inhibition. Interference
of the hormone-activated GR with nuclear factor (NF)-kB
Enhanced interleukin-6 levels following painful stimulation in patients with fibromyalgia 681signaling pathway by means of an increased production of
glucocorticoid inducible leucine zipper (GILZ) in monocytes
has been identified as an important step within this transduc-
tion process (Clark, 2007; Eddleston et al., 2007; De Bosscher
and Haegeman, 2009). PBMCs of FMS patients have recently
been found to contain significantly lower levels of GILZ in
comparison with controls (Macedo et al., 2008). This raises
the possibility that FMS patients’ higher IC50 for LPS-induced
IL-6 production does partly reflect a reduced expression of
GILZ and hence abnormal NF-kB activation in their circulating
monocytes (Eddleston et al., 2007).
Exclusion of subjects having taken long-term antidepres-
sant medication from participation and examination of
mainly premenopausal women in the current study may
provide an explanation for the inconsistency between pre-
sent and findings by Wingenfeld et al. (2008) and Macedo
et al. (2008) as participants in Macedo’s study were allowed
to participate after discontinuing medication for two weeks,
and Wingenfeld et al. did examine mainly postmenopausal
women. There is in vitro evidence suggesting that transduc-
tion of cortisol signal into cytokine inhibition may be decel-
erated by reduced estradiol availability during menopause as
fewer estrogen receptors (ER) are occupied by this hormone
(Liu et al., 2005). Long-term antidepressant medication may
accelerate the transduction of cortisol signal into cytokine
inhibition because incubation of whole blood samples for 24 h
with amitriptyline has been demonstrated to induce an
upregulation of GR expression (Vedder et al., 1999).
The revealed reduced GC sensitivity of circulating mono-
cytes in FMS patients is indicative of a hypercortisolemic
pattern in this population. In conflicting with a hypercortiso-
lemic pattern FMS patients did exhibit a normal daytime
cortisol profile and HPA axis feedback sensitivity. FMS patients
were, on average, above the threshold for a diagnosis of MDD on
the CES-D. The PHQ-D identified two FMS patients as conform-
ing with criteria for a threshold diagnosis of MDD indicative of
MDD presence in a subgroup of FMS patients. In line with this
finding, subgroups and not the general population of FMS
patients have been reported previously to experience signifi-
cant depressive symptomatology (Ahles et al., 1987; Ferrac-
cioli et al., 1990). Although threshold diagnosis of MDD in FMS
patients needs to be confirmed by structured interviews it
seems unlikely that a depressive-like hypercortisolemia may
account for altered HPA axis function in FMS patients.
It might be argued that exclusion of FMS patients having
taken antidepressant medication for a long time increases
the risk of having a sub-group of patients which are not
representative of FMS patients in general. Exclusion of FMS
patients having taken antidepressant medication for a long
time was necessary as long-term amitriptyline medication
has been identified as a confounder of GC sensitivity of
circulating monocytes in in vitro and our pilot studies (Oku-
gawa et al., 1999; Vedder et al., 1999). The currently exam-
ined FMS patients are representative of FMS patients in
general as they are comparable to previous populations on
psychosocial variables. For instance, the mean age of the
currently studied FMS patients is representative of the age
group having a high prevalence for this disorder (Wolfe et al.,
1995). Consistent with previous findings a minority of the
currently examined FMS patients did experience significant
depressive symptomatology (Ahles et al., 1987; Ferraccioli
et al., 1990).Whereas FMS patients did not differ from controls in their
IL-6 levels before PPT measurement, their IL-6 levels
increased approximately 300% above baseline after PPT
measurement. The enhanced IL-6 reactivity in FMS patients
after pressure application on their tender points provides the
first line of evidence for elevated IL-6 levels after painful
stimulation in this population.
Muscle cells may represent a cellular origin of enhanced IL-6
reactivity after pressure application on tender points in FMS
patients as painful stimulation of muscles has been demon-
strated to increase circulating IL-6 levels in humans and animals
(Loram et al., 2007; Edwards et al., 2008). In more detail,
muscle-derived IL-6 may elevate circulating IL-6 levels by the
demonstrated potency of this cytokine to sensitize muscle
nociceptors through induction of prostaglandin (PG)E2 synthesis
(Lahiri et al., 2001). Sensitized muscle nociceptors release the
monocyte attractant neuropeptide substance P (SP) which has
been shown in vitro to be able to increase circulating IL-6 levels
by binding to a non-neurokinin SP receptor on monocytes (Kave-
laars et al., 1994; Schratzberger et al., 1997; Mense, 2003).
Although FMS patient’s epinephrine concentrations
remained at low levels at all time points before and after
PPT measurement their norepinephrine concentrations did
increase significantly from 10 min pre-testing to 10 min post-
testing. In line with present findings low epinephrine levels
have been detected consistently in FMS patients after
exposure to different types of stressors (Giske et al., 2008;
Kadetoff and Kosek, 2010).
High norepinephrine along with low epinephrine levels are
indicative of a reduced cortisol production in the adrenal cortex
as decreased cortisol production gives rise to a lower norepi-
nephrine to epinephrine conversion in the adrenal medulla
(Wurtman and Axelrod, 1966). A stress or inflammation-related
dissociation between the hypothalamic—pituitary-system and
the adrenal cortex has been related to an adrenal insufficiency
(Nussdorfer, 1996; Ehrhardt-Bornstein et al., 1998).
Elevated cortisol levels after PPT measurement which
were not preceded by an ACTH increase in FMS patients
are indicative of a dissociation between the hypothala-
mic—pituitary-system and adrenal cortex. Norepinephrine
and IL-6 have been identified as ACTH-independent stimuli
which are able to compensate for a diminished potency of
ACTH to induce adrenal steroid genesis (Bornstein and Chrou-
sos, 1999; Bornstein et al., 2008). Their involvement in the
induction of FMS patient’s post-algesimetric adrenocortical
activation is suggested by coincidence of elevated norepi-
nephrine levels with first cortisol peak 10 min and increased
IL-6 levels with second cortisol peak 240 min after PPT
measurement in FMS patients. There is further evidence
implying the involvement of norepinephrine and IL-6 in the
induction of an ACTH-independent adrenocortical activation.
For instance, Alzheimer Disease patients were found to
exhibit an early cortisol response following painful stimula-
tion which was not preceded by elevated ACTH levels, but
accompanied by increased norepinephrine levels (Pascualy
et al., 2000). Furthermore, healthy participants have been
reported to display an early cortisol response, but delayed IL-
6 response after painful stimulation (Edwards et al., 2008).
As compared with FMS patients controls did exhibit signifi-
cantly elevated ACTH levels 30 min before PPT measurement
indicative of an anticipation effect. ACTH increase 30 min pre-
testing was not accompanied by a pre-algesimetric cortisol
682 A. Geiss et al.response in controls. Increased cortisol levels have been shown
to be dependent on preceding elevation of ACTH levels (Kirsch-
baum et al., 1993). Decline in control’s ACTH levels from
30 min to 10 min pre-testing may account for the lack in their
pre-algesimetric cortisol response.
Several limitations of our study should be noted. First, the
study is limited by a small sample size. Second, we did not
measure total cortisol levels and DEX levels following late-
night administration of DEX. As FMS patients’ circulating
monocytes were found to be less sensitive to the immuno-
suppressive actions of DEX it is conceivable that their post-
DEX cortisol values following DEX administration have been
modulated by their reduced GC sensitivity (Lowy and Meltzer,
1987).
To summarize, the present findings do not support the
hypothesis that FMS core symptoms pain and fatigue are
promoted by reduced cortisol levels. Instead, they indicate
that deficiencies in the GR signaling pathway in circulating
monocytes may contribute to the maintenance of FMS core
symptoms pain and fatigue by facilitating an enhanced IL-6
reactivity.
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